8-Propyl-6H-[1,3]dioxolo[4,5-g]chromen-6-one: A new coumarin with monoamine oxidase B inhibitory activity and possible anti-parkinsonian effects

Authors

  • María del Pilar Olaya Universidad Nacional de Colombia, Facultad de Ciencias, Departamento de Farmacia
  • Nadezdha Esperanza Vergel Universidad Nacional de Colombia, Facultad de Ciencias, Departamento de Farmacia
  • Jose Luis López Salamanca University, School of Pharmacy, Pharmaceutical Chemistry Department
  • Dolores Viña University of Santiago de Compostela, Center for Research in Molecular Medicine and Chronic Diseases, Pharmacology Department https://orcid.org/0000-0001-5777-1955
  • Mario Francisco Guerrero Universidad Nacional de Colombia, Facultad de Ciencias, Departamento de Farmacia

DOI:

https://doi.org/10.1590/s2175-97902019000317609

Keywords:

Parkinson’s disease, Monoamine oxidase B, Coumarin, Mice, Reserpine, Levodopa, Carbidopa

Abstract

Parkinson’s disease is a common neurodegenerative disorder. In this study, the monoamine oxidase inhibitory activity and potential anti-parkinsonian effects of 8-propyl-6H-[1,3]dioxolo[4,5-g]chromen6-one (FCS303), a new synthetic coumarin, were evaluated. To do this, we used the reserpine model of Parkinson’s disease, an assay of levodopa/carbidopa potentiation, the catalepsy model of haloperidol, and an in vitro assay against monoamine oxidase (MAO) activity. Additionally, lipid peroxidation and protein carbonyl group quantification was performed in mice brain homogenates previously treated with haloperidol. FCS303 inhibited monoamine oxidase B (MAO-B) with an IC50 of 5.46 ± 0.36 µM; however, there was no effect on monoamine oxidase A (MAO-A). The oral administration of FCS303 led to a significant reversal of hypokinesia in the reserpine model (at 24 h, doses of 100 and 200 mg/kg) and in the levodopa/carbidopa potentiation assay (at 2 and 24 h, dose of 200 mg/kg). In addition, FCS303 (100 mg/kg) showed anti-cataleptic activity against haloperidol. FCS303 (50 mg/kg) significantly decreased lipid peroxidation and protein carbonyl quantification. These results suggest that FCS303 could present anti-parkinsonian activity related to MAO-B inhibitory activity.

Downloads

Download data is not yet available.

Downloads

Published

2020-12-09

How to Cite

Olaya, M. del P. ., Vergel, N. E. ., López, J. L. ., Viña, D. ., & Guerrero, M. F. . (2020). 8-Propyl-6H-[1,3]dioxolo[4,5-g]chromen-6-one: A new coumarin with monoamine oxidase B inhibitory activity and possible anti-parkinsonian effects. Brazilian Journal of Pharmaceutical Sciences, 56, e17609. https://doi.org/10.1590/s2175-97902019000317609

Issue

Section

Article